Greenfield-based Elanco Animal Health has announced a new partnership with a team of agbiosciences researchers in Wisconsin. The global in-licensing agreement with Ab E Discovery involves technology focused on improving gut health of poultry. The technology is in the late stages of development and involves hens passing along anti-bodies to offspring through eggs.

Under terms of the agreement, Elanco has the exclusive global rights for all animal species, but the initial focus will be on poultry. Elanco says it intends to deliver up to 25 viable antibiotic alternative development projects addressing "critical unmet challenges in livestock production and reduce the need for shared-class antibiotics that are also critical to human medicine" by 2020.

You can connect to more about the agreement by clicking here.